1999•PubMedRequires access

[Drug of the month. Sildenafil (Viagra)].

Robert Andrianne

Open publisher page 2 citations

Abstract

Sildenafil (Viagra) from Pfizer (UK-92,480) is a competitive and selective inhibitor of cyclic GMP specific type 5 phosphodiesterase. Male erectile dysfunction is defined as "the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance". Sildenafil (Viagra) is effective in a significant proportion of patients with erectile dysfunction. Patients should be instructed to take a dose from 25 to 100 mgrs approximately 30 to 60 minutes before sexual activity, but no more than once daily. Sexual stimulation is necessary to produce erectile reaction. The safety and tolerance of sildenafil have been demonstrated. However, prior to initiating treatment with sildenafil, physicians should consider the cardiovascular status of their patients, particularly for patients with unstable coronary heart disease or concomitant treatment with nitrates.

About this research paper

What this paper is about

Sildenafil (Viagra) from Pfizer (UK-92,480) is a competitive and selective inhibitor of cyclic GMP specific type 5 phosphodiesterase. Male erectile dysfunction is defined as "the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance". Sildenafil (Viagra) is effective in a significant proportion of patients with erectile dysfunction. Patients should be instructed to take a dose from 25 to 100 mgrs approximately 30 to 60 minutes before sexual activity, but no more than once daily. Sexual stimulation is necessary to produce erectile reaction. The safety and tolerance of sildenafil have been demonstrated. However, prior to initiating treatment with sildenafil, physicians should consider the cardiovascular status of their patients, particularly for patients with unstable coronary heart disease or concomitant treatment with nitrates.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Sildenafil (Viagra) from Pfizer (UK-92,480) is a competitive and selective inhibitor of cyclic GMP specific type 5 phosphodiesterase. Male erectile dysfunction is defined as "the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance". Sildenafil (Viagra) is effective in a significant proportion of patients with erectile dysfunction. Patients should be instructed to take a dose from 25 to 100 mgrs approximately 30 to 60 minutes before sexual activity, but no more than once daily. Sexual stimulation is necessary to produce erectile reaction. The safety and tolerance of sildenafil have been demonstrated. However, prior to initiating treatment with sildenafil, physicians should consider the cardiovascular status of their patients, particularly for patients with unstable coronary heart disease or concomitant treatment with nitrates.

Key concepts: Sildenafil, Erectile dysfunction, Sexual stimulation, Medicine, Concomitant, cGMP-specific phosphodiesterase type 5, Heart disease, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
[Drug of the month. Sildenafil (Viagra)]. — Research Paper | ScholarLens